OR9
(6aR)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol
Created: | 2020-08-24 |
Last modified: | 2021-02-24 |
Find Related PDB Entry |
---|
Find related ligands: |
---|
Chemical Details | |
---|---|
Formal Charge | 0 |
Atom Count | 37 |
Chiral Atom Count | 1 |
Bond Count | 40 |
Aromatic Bond Count | 12 |
Chemical Component Summary | |
---|---|
Name | (6aR)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol |
Systematic Name (OpenEye OEToolkits) | (6~{a}~{R})-6-methyl-5,6,6~{a},7-tetrahydro-4~{H}-dibenzo[de,g]quinoline-10,11-diol |
Formula | C17 H17 N O2 |
Molecular Weight | 267.322 |
Type | NON-POLYMER |
Chemical Descriptors | |||
---|---|---|---|
Type | Program | Version | Descriptor |
SMILES | ACDLabs | 12.01 | C12Cc4ccc(c(c4c3c1c(CCN2C)ccc3)O)O |
SMILES | CACTVS | 3.385 | CN1CCc2cccc3c2[CH]1Cc4ccc(O)c(O)c34 |
SMILES | OpenEye OEToolkits | 2.0.7 | CN1CCc2cccc-3c2C1Cc4c3c(c(cc4)O)O |
Canonical SMILES | CACTVS | 3.385 | CN1CCc2cccc3c2[C@H]1Cc4ccc(O)c(O)c34 |
Canonical SMILES | OpenEye OEToolkits | 2.0.7 | CN1CCc2cccc-3c2[C@H]1Cc4c3c(c(cc4)O)O |
InChI | InChI | 1.03 | InChI=1S/C17H17NO2/c1-18-8-7-10-3-2-4-12-15(10)13(18)9-11-5-6-14(19)17(20)16(11)12/h2-6,13,19-20H,7-9H2,1H3/t13-/m1/s1 |
InChIKey | InChI | 1.03 | VMWNQDUVQKEIOC-CYBMUJFWSA-N |
Drug Info: DrugBank
DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License
DrugBank ID | DB00714 |
---|---|
Name | Apomorphine |
Groups |
|
Description | Apomorphine is a non-ergoline dopamine D2 agonist indicated to treat hypomobility associated with Parkinson's. It was first synthesized in 1845 and first used in Parkinson's disease in 1884.[A203618] Apomorphine has also been investigated as an emetic, a sedative, a treatment for alcoholism, and a treatment of other movement disorders.[A203597,A203618] Apomorphine was granted FDA approval on 20 April 2004.[L13919] |
Synonyms |
|
Brand Names |
|
Indication | Apomorphine is indicated to treat acute, intermittent treatment of hypomobility, off episodes associated with advanced Parkinson's disease.[L13919,L13922] |
Categories |
|
ATC-Code |
|
CAS number | 58-00-4 |
Drug Targets
DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License
Name | Target Sequence | Pharmacological Action | Actions |
---|---|---|---|
D(4) dopamine receptor | MGNRSTADADGLLAGRGPAAGASAGASAGLAGQGAAALVGGVLLIGAVLA... | unknown | agonist |
D(2) dopamine receptor | MDPLNLSWYDDDLERQNWSRPFNGSDGKADRPHYNYYATLLTLLIAVIVF... | unknown | agonist |
D(3) dopamine receptor | MASLSQLSGHLNYTCGAENSTGASQARPHAYYALSYCALILAIVFGNGLV... | unknown | agonist |
D(1B) dopamine receptor | MLPPGSNGTAYPGQFALYQQLAQGNAVGGSAGAPPLGPSQVVTACLLTLL... | unknown | agonist |
D(1A) dopamine receptor | MRTLNTSAMDGTGLVVERDFSVRILTACFLSLLILSTLLGNTLVCAAVIR... | unknown | agonist |
View More |
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682
Related Resource References
Resource Name | Reference |
---|---|
Pharos | CHEMBL53 |
PubChem | 6005 |
ChEMBL | CHEMBL53 |
ChEBI | CHEBI:48538 |
CCDC/CSD | FIKFIP |